Our Startups
Enterprise Innovation has launched a diverse portfolio of companies that are based on foundational intellectual property developed in the research laboratories of Weill Cornell Medicine. Our current portfolio of companies encompasses key health-care verticals including diagnostics, digital health, therapeutics, medical devices, and R&D products and services.
Weill Cornell Medicine Startups
EIR Biopharma, Inc. is an early-stage privately held biotech company developing therapeutics for the treatment of eye disease. We have partnered with Weill Cornell Medicine for the treatment of atrophic “Dry” age-related macular degeneration, and the University of Miami’s Bascom Palmer Eye Institute for the treatment of glaucoma. Our founders have over 50 years of senior level management experience in the biotechnology, pharmaceutical and biopharma industries, and have helped to create publicly traded biopharma companies with peak market capitalizations exceeding $15 billion.
Faeth Therapeutics, Inc. is a data-driven, evidence-based healthcare company, with a mission to rethink the role of nutrition in the fight against cancer.
Fesarius Therapeutics is developing engineered tissue scaffold products for the skin and dermal layers. The products are based off the patent-pending microstructure-containing gel scaffold technology developed at Cornell. The acellular skin replacement will aim to benefit those with wounds resulting from burns, plastic surgery, tumor removal and other forms of trauma. The company joined the National Institutes of Health as part of its I-Corps @ NIH Winter 2020 Program in February 2020.
Fitzroy Salute, LLC offers an affordable and comprehensive environmental health and safety information management solution to streamline and improve EHS operations. The cloud-based IMS provides environmental health and safety staff with integrated modules for hazard assessment, safety and compliance, metric tracking and more. Fitzroy Salute, LLC provides academic and healthcare institutions the tools they need to foster a true culture of safety, rather than just compliance.
Guard Medical, a privately-held company, is developing easy-to-use and cost-effective solutions that enable prophylactic Negative Pressure Wound Therapy (NPWT) wound care of closed surgical incisions. Guard Medical’s simple NPWT technology originated with NewYork-Presbyterian/Weill Cornell Medical Center in response to physicians’ identification of unmet needs related to Surgical Site Infections (SSI). Its investors include Bpifrance and Matignon Investissement et Gestion. Guard Medical’s vision is to develop NPWT solutions for use on a wide range of surgical wound types and sizes with broad applications for infection prevention, scar mitigation and enhanced cosmesis.
IpiNovyx Bio is developing multiple series of highly selective, ultra potent small molecule therapeutics for the treatment of autoimmune and inflammatory disorders.
Larkspur Biosciences, Inc.
LEXEO Therapeutics is a New York City-based clinical-stage gene therapy company focused on addressing some of the most devastating genetically defined cardiovascular and central nervous system diseases. LEXEO is advancing a deep and diverse pipeline of AAV-based gene therapy candidates utilizing a modular approach designed to overcome many of the challenges facing the field of gene therapy. It applies cutting-edge science to target the underlying causes of diseases affecting both larger-rare and prevalent patient populations.
Lucerna, Inc., is a biotechnology research company focused on developing and commercializing nucleic-acid based fluorescent sensors for Point-of-Care therapeutic diagnostics and environmental biomonitoring. Lucerna also offers newly developed antibodies for proteomic research.
Lumendi develops devices that enable less invasive endoluminal procedures in the GI tract, primarily in the colon. These devices have the potential to replace many invasive laparoscopic and open surgical procedures performed in hospital settings.
Lumidyne Technologies offers a suite of organic fluorophores spanning the visible spectrum that exhibit unprecedented enhancements in fluorophore performance. These new fluorophores have been optimized to fit all pre-existing imaging platforms with a range of activating chemistries suitable for existing and future investigations that would benefit from increased brightness, longevity and time resolution.
MedExplain is designed to meet the needs of patients and their loved ones who want plain facts about drugs, health and disease. It is a publicly available resource designed to provide engaging, easily understood and well-researched articles by doctors for people who want to know more about health, medicines and diseases.